Triterpenoid CDDO-Im downregulates PML/RARα expression in acute promyelocytic leukemia cells

Cell Death and Differentiation

Volumn 12, Issue 5, 2005, Pages 523-531

  Ikeda, T ^a   Kimura, F ^b   Nakata, Y ^b   Sato, K ^b   Ogura, K ^b   Motoyoshi, K ^b   Sporn, M ^c   Kufe, Donald ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

ATO; ATRA; CDDO Im; PML; PML RAR

Indexed keywords

2 CYANO 3,12 DIOXOOLEANA 1,9 DIEN 28 OIC ACID; ARSENIC TRIOXIDE; HYBRID PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID RECEPTOR ALPHA; TRITERPENOID; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DEATH; CELL DIFFERENTIATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKEMIA CELL LINE; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION;

APOPTOSIS; ARSENICALS; CASPASES; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMIDAZOLES; LEUKEMIA, PROMYELOCYTIC, ACUTE; NEOPLASM PROTEINS; NUCLEAR PROTEINS; OLEANOLIC ACID; OXIDES; RECEPTORS, RETINOIC ACID; RECOMBINANT FUSION PROTEINS; TRANSCRIPTION FACTORS; TRETINOIN; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

ATRA;

EID: 18644375251     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401574     Document Type: Article

References (41)

1. Kakizuka A, Miller Jr. WH, Umesono K, Warrell Jr. RP, Frankel SR, Murty VV, Dmitrovsky E and Evans RM (1991) Chromosomal translocation t(15:17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML. Cell 66: 663-674
2. de The H, Lavau C, Marchio A, Chomienne C, Degos L and Dejean A (1991) The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66: 675-684
3. Tallmann M, Anderson J and Schiffer C (1997) All-transretinoic acid in acute promyelocytic leukemia. N. Engl. J. Med. 337:1021-1028
4. Burnett AK, Grimwade D, Solomon E, Wheatley K and Goldstone AH (1999) Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood 93: 4131-4143
5. Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, Fey M, Rayon C, Huguet F, Sotto JJ, Gardin C, Makhoul PC, Travade P, Solary E, Fegueux N, Bordessoule D, Miguel JS, Link H, Desablens B, Stamatoullas A, Deconinck E, Maloisel F, Castaigne S, Preudhomme C and Degos L (1999) A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 94: 1192-1200
6. Sanz MA, Martin G, Rayon C, Esteve J, Gonzalez M, Diaz-Mediavilla J, Bolufer P, Barragan E, Terol MJ, Gonzalez JD, Colomer D, Chillon C, Rivas C, Gomez T, Ribera JM, Bornstein R, Roman J, Calasanz MJ, Arias J, Alvarez C, Ramos F and Deben G (1999) A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARαlpha-positive acute promyelocytic leukemia. PETHEMA group. Blood 94: 3015-3021
7. Dombret H, Fenaux P, Soignet SL and Tallman MS (2002) Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapy. Semin. Hematol. 39: 8-13
8. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP and Warrell Jr. RP (1998) Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med. 339: 1341-1348
9. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang F, Zhang TD, Chen SJ, Chen Z and Wang ZY (1997) Use of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89: 3354-3360
10. Dai J, Weinberg RS, Waxman S and Jing Y (1999) Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 93: 268-277
11. Suh N, Wang Y, Honda T, Gribble GW, Dmitrovsky E, Hickey WF, Maue RA, Place AE, Porter DM, Spinella MJ, Williams CR, Wu G, Dannenberg AJ, Flanders KC, Letterio JJ, Mangelsdorf DJ, Nathan CF, Nguyen L, Porter WW, Ren RF, Roche NS, Subbaramaiah K and Sporn MB (1999) A novel synthetic oleanane triterpenoid, 2-cyno-3, 12-dioxoolean-1, 9-dien-28-oic acid, with potent differentiating, antiproliferative and anti-inflammatory activity. Cancer Res. 59: 336-341
12. Ito Y, Pandey P, Place A, Sporn M, Gribble G, Honda T, Kharbanda S and Kufe D (2000) The novel triterpenoid CDDO induces apoptosis of human myeloid leukemia cells by a caspase-8 dependent mechanism. Cell Growth Differ. 11: 261-267
13. Ito Y, Pandey P, Sporn M, Datta R, Kharbanda S and Kufe D (2001) The novel triterpenoid CDDO induces apoptosis and differentiation of human osteosarcoma cells by a caspase-8 dependent mechanism. Mol. Pharmacol. 59: 1094-1099
14. Pedersen I, Kitada 5, Schimmer A, Kim Y, Zapata J, Chamoneau L, Rassenti L, Andreeff M, Bennett F, Sporn M, Liotta L, Kipps T and Reed J (2002) The triterpenoid CDDO induces apoptosis in refractory CLLB cells. Blood 100: 2965-2972
15. Stadheim TA, Suh N, Ganju N, Spain MB and Eastman A (2002) The novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) potently enhances apoptosis induced by tumor necrosis factor in human leukemia cells. J. Biol. Chem. 277: 16448-16455
16. Zou W, Liu X, Yue P, Zhou Z, Sporn MB, Lotan R, Khuri FR and Sun SY (2004) c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells. Cancer Res. 64: 7570-7578
17. Ikeda T, Sporn M, Honda I, Gribble G and Kufe D (2003) The novel triterpenoid CDDO induces apoptosis by disruption of intracellular redox balance. Cancer Res. 63: 5551-5558
18. Konopleva M, Tsao T, Ruvolo F, Stiouf I, Estrov Z, Leysath CE, Zhao S, Harris O, Chang S, Jackson CE, Munsell M, Suh N, Gribble G, Honda T, May WS, Sporn MB and Andreeff M (2002) Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood 99: 326-335
19. Place AE, Suh N, Williams CR, Risingsong R, Honda T, Honda Y, Gribble GW, Leesnitzer LM, Stimmel JB, Willson TM, Rosen E and Sporn MB (2003) The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin. Cancer Res. 9: 2798-2806
20. Grignani F, Ferrucci PF, Testa U, Talamo G, Fagioli M, Alcalay M, Mencarelli A, Grignani F, Peschle C, Nicoletti I and Pelicci PG (1993) The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 74: 423-431
21. Daniel MT, Koken M, Romagne O, Barbey S, Bazarbachi A, Stadle M, Guillemin MC, Degas L, Chomienne C and de The H (1993) PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood 82: 1858-1867
22. Pedersen IM, Zapata JM, Samuel T, Scott FL, Salvesen GS, Honda T, Gribble GW, Suh N, Sporn MB, Kipps TJ and Reed JC (2004) Retraction: the triterpenoid CDDO-imidazolide induces apoptosis and enhances fludarabine-induced apoptosis of CLL B-cells. Blood 104: 932
23. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG and Waxman S (1999) Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 94: 2102-2111
24. Wang Y, Porter WW, Suh N, Honda T, Gribble GW, Leesnitzer LM, Plunket KD, Mangelsdorf DJ, Blanchard SG, Willson TM and Spain MB (2000) A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma. Mol. Endocrinol. 14: 1550-1556
25. Snow ET (1992) Metal carcinogenesis: mechanistic implications. Pharmacol. Ther. 53: 31-65
26. Chen Z, Chen GQ, Shen ZX, Chen SJ and Wang ZY (2001) Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies. Semin. Hematol. 38: 26-36
27. Miller S, Walker SW, Arthur JR, Lewin MH, Pickard K, Nicol F, Howie AF and Beckett GJ (2002) Selenoprotein expression in endothelial cells from different human vasculature and species. Biochim. Biophys. Acta 1588: 85-93
28. Warrell Jr. RP (1993) Retinoid resistance in acute promyelocytic leukemia: new mechanisms, strategies, and implications. Blood 82: 1949-1953
29. Lefebvre P, Thomas G, Gourmel B, Agadir A, Castaigne S, Dreux C, Degao L and Chomienne C (1991) Pharmacokinetics of oral all-trans retinoic acid in patients with acute promyelocytic luekemia. Leukemia 5: 1054-1058
30. Muindi JR, Frankel SR, Huselton C, DeGrazia F, Garland WA, Young CW and Warrell Jr. RP (1992) Clinical pharmacology of oral all- trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res. 52: 2138-2142
31. Moran LK, Gutteridge JM and Quinlan GJ (2001) Thiols in cellular redox signalling and control. Curr. Med. Chem. 8: 763-772
32. Nordberg J and Arner E (2001) Reactive oxygen species, antioxidants, and mammalian thioredoxin system. Free Radic. Biol. Med. 31: 1287-1312
33. Kitamura K, Minami Y, Yamamoto K, Akao Y, Kiyoi H, Saito H and Naoe T (2000) Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis. Leukemia 14: 1743-1750
34. Liu Q, Hilsenbeck S and Gazitt Y (2003) Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood 101: 4078-4087
35. Duprez E, Lillehaug JR, Naoe T and Lanotte M (1996) cAMP signalling is decisive for recovery of nuclear bodies (PODs) during maturation of RA-resistant t(15;17) promyelocytic leukemia NB4 cells expressing PML-RAR alpha. Oncogene 12: 2451-2459
36. Honda T, Honda Y, Favaloro Jr. FG, Gribble GW, Suh N, Place AE, Rendi MH and Sporn MB (2002) A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production. Bioorg. Med. Chem. Lett. 12: 1027-1030
37. Yoshida K, Weichselbaum R, Kharbanda S and Kufe D (2000) Role for Lyn tyrosine kinase as a regulator of stress-activated protein kinase activity in response to DNA damage. Mol. Cell. Biol. 20: 5370-5380
38. Chen A, Licht JD, Wu Y, Hellinger N, Scher W and Waxman S (1994) Retinoic acid is required for and potentiates differentiation of acute promyelocytic leukemia cells by nonretinoid agents. Blood 84: 2122-2129
39. Lizard G, Gueldry S, Sordet O, Monier S, Athias A, Miguet O, Bessede G, Lemaire S, Salary E and Gambert P (1998) Glutathione is implied in the control of 7-ketocholesterol-induced apoptosis, which is associated with radical oxygen species production. FASEB J. 12: 1651-1663
40. Karp OR, Shimooku K and Lipsky FE (2001) Expression of gamma-glutamyl transpeptidase protects ramos B cells from oxidation-induced cell death. J. Biol. Chem. 276: 3798-3804
41. Shapiro HM (2000) Membrane potential estimation by flow cytometry. Methods 21: 271-279